AI Regulation Tracker / Agency organization
FDA has given AI a standing division inside CDER, and that is all this notice does
The revised Statement of Organization published 29 July 2026 lists a Division of Artificial Intelligence, unit code DCDHDB, inside the drugs centre. It is an org chart. It asks nothing of any sponsor.
What did FDA actually file?
A list. That is the honest description. The document restates FDA's organizational chart from the Office of the Commissioner down through each centre, unit by unit, with the internal code for each one. The stated rationale is that the agency plans "to centralize and enhance key functions across the agency" and that the changes "will reduce redundancies, improve efficiency, and advance alignment to better serve the American public."
Inside the CDER section, headed "DCD. ORGANIZATION. The Center for Drug Evaluation and Research includes the following organizational units", four lines run in sequence:
OFFICE OF INNOVATION AND CLINICAL TRIAL MODERNIZATION (DCDHD)
CLINICAL METHODOLOGY STAFF (DCDHD1)
DIVISION OF REAL-WORLD EVIDENCE ANALYTICS (DCDHDA)
DIVISION OF ARTIFICIAL INTELLIGENCE (DCDHDB)91 FR 47839, FR Doc. 2026-15297
That is the entire textual basis for this story. The notice says nothing else about the division: not its functions, not its staffing, not its director, not its remit. It gives it a name, a code and a place in a hierarchy.
The chain runs: Center for Drug Evaluation and Research (DCD), Office of Medical Policy (DCDH), Office of Innovation and Clinical Trial Modernization (DCDHD), Division of Artificial Intelligence (DCDHDB). Office of Medical Policy is the same office that houses prescription drug promotion review and medical policy development. That is a policy home rather than a review-division home.
Who now owns an AI question in a drug or biologics submission?
Structurally, there is now a named unit to point at. Practically, the answer for a working regulatory affairs team has not moved yet, and it would be a mistake to tell a client otherwise.
Review of an application still runs through the divisions that were already reviewing it. Nothing here reassigns a submission, changes a review clock or creates a pathway. What a standing division gives a sponsor is a stable name to reference in correspondence and in meeting requests, and a place in the chart that will not evaporate when a working group's charter expires. Task forces come and go. A division with a unit code appears in the Staff Manual Guide.
There is a second signal in the placement, and it is the one worth a note in the file. The Division of Artificial Intelligence is listed beside the Division of Real-World Evidence Analytics, under an office whose name is about clinical trial modernization. Read the neighbours rather than the label. On this chart, AI in the drugs centre is grouped with evidence generation and trial conduct, not with product review and not with information technology. That is an observation from the document, not a prediction.
Does a sponsor have to do anything by a date?
No. There is no date to diary. The notice has no DATES section, no compliance date and no comment period, and it is not a proposed rule, so there is nothing to comment on. The only operative paragraph aimed at anyone is Section II, and it is a continuity clause rather than a change:
Pending further delegation, directives, or orders by the Commissioner of Food and Drugs, all delegations and redelegations of authority made to officials and employees of affected organizational components will continue in them or their successors pending further redelegations, provided they are consistent with this reorganization.Section II, Delegations of Authority, FR Doc. 2026-15297
In plain terms: signatures valid before this filing stay valid after it. Section III adds that the reorganization "will be reflected in FDA's Staff Manual Guide", which is the document to watch, not this notice.
Why is this different from the device classification stories?
Because the two do different work, and conflating them is how a briefing note goes wrong. The tracker has been running a steady line of product classification coverage: the MHRA drawing the line on when an ambient voice product becomes a regulated medical device, and FDA's own clinical decision support boundary. Those decisions change what a product is in law. Get on the wrong side of one and a manufacturer is marketing an unregistered device.
This notice changes none of that. It changes an address. Nobody's product becomes a device and no marketing claim becomes actionable. A structural filing and a classification decision belong in different sections of the same memo.
Where does an AI question go, by instrument type?
The comparison below sets this notice against the other AI-named or AI-facing units and instruments a life sciences team deals with. The axis is not "who is doing more on AI". It is what kind of document each one is, and therefore what it can be used for.
| Unit or instrument | Product scope | What the source document is | Does it create a duty for industry |
|---|---|---|---|
| Division of Artificial Intelligence (DCDHDB), FDA CDER | Drugs and biologics | A line on an organizational chart in a Federal Register notice, 29 July 2026 | No. No functions stated, no standard set |
| Digital Health Center of Excellence (DCCCF), FDA CDRH | Medical devices, including software as a medical device | Also a chart entry in the same notice, retained with its Divisions of Digital Health Policy, Technology Assessment and Outreach | No, not from this notice. Device duties come from device law and guidance |
| Artificial Intelligence Governance Branch (DCNAHA2), FDA Office of Operations | FDA's own use of AI and data | A chart entry under the Office of Data Governance and Privacy. Printed in the notice as "ARTIFICAL INTELLIGENCE GOVERNANCE BRANCH", spelling as filed | No. It is inward facing |
| MHRA guidance on ambient voice technology, Great Britain | AI scribing and ambient documentation products | Published regulatory guidance on device qualification, not an organizational statement | Yes in effect. It decides whether a product is a regulated device |
The fourth row shows the difference cleanly. Three chart entries and one qualification decision, and only the qualification decision moves a product's legal status.
Is this really the first Division of Artificial Intelligence in the Federal Register?
The claim is narrower than it sounds, so here is the search and its limits rather than the headline. A full-text query of the Federal Register's public API for the exact phrase "DIVISION OF ARTIFICIAL INTELLIGENCE", run through the documents search with the term condition set to the quoted phrase, returns a count of one, and the single result is this document. A control query confirms the same index reaches back to at least February 1994, so this is roughly three decades of the corpus rather than the whole history of the publication.
Two caveats cut against overreading it. A search of the Federal Register tells you when a phrase was printed there, not when a unit came into existence. FDA components can be established or renamed through the Staff Manual Guide without a contemporaneous notice, so first appearance in print is not first existence, and this piece does not claim the division is new. And the same notice contains an AI-named branch spelled "ARTIFICAL", a reminder that phrase searches over agency filings miss what agencies mistype.
What the notice does not say
Worth listing, because secondary coverage of a filing like this tends to fill the gaps with inference.
- It does not state the division's functions. The CDER section is a list of units and codes.
- It does not name a director, state a headcount, or say whether staff are being moved, hired or redesignated.
- It does not announce guidance, a pilot, a docket or a public meeting.
- It does not change how AI or machine learning components of a drug submission are reviewed, or by whom.
- It does not say the division is new. It says the Statement of Organization has been revised.
- It does not touch the device pathway. CDRH keeps its digital health units in the same document.
Where the trade press describes a launch, a mandate or a remit, that description is not coming from FR Doc. 2026-15297. I am declining to repeat it here for that reason.
Frequently asked questions
Does the FDA reorganization notice require anything of drug sponsors?
No. FR Doc. 2026-15297 is a Statement of Organization, Functions, and Delegations of Authority published as a Notice at 91 FR 47835 on 29 July 2026. It revises FDA's own organizational chart. It sets no submission requirement, no review standard and no comment period, and it is not a substantive rule on regulated parties.
Where does the Division of Artificial Intelligence sit inside FDA?
The notice lists DIVISION OF ARTIFICIAL INTELLIGENCE (DCDHDB) under the OFFICE OF INNOVATION AND CLINICAL TRIAL MODERNIZATION (DCDHD), which sits under the OFFICE OF MEDICAL POLICY (DCDH) within the Center for Drug Evaluation and Research (DCD). Its listed siblings are CLINICAL METHODOLOGY STAFF (DCDHD1) and DIVISION OF REAL-WORLD EVIDENCE ANALYTICS (DCDHDA).
Does the notice say what the Division of Artificial Intelligence will do?
No. The CDER section of the notice is a list of organizational units and their unit codes. It states no functions, no staffing and no remit for the division, and it announces no guidance. Any account of what the division will review or publish would go beyond the document.
What happens to existing FDA delegations of authority?
Section II of the notice states that pending further delegation, directives, or orders by the Commissioner of Food and Drugs, all delegations and redelegations of authority made to officials and employees of affected organizational components will continue in them or their successors pending further redelegations, provided they are consistent with the reorganization. The notice adds that the reorganization will be reflected in FDA's Staff Manual Guide.
Is this the same thing as the MHRA classifying AI scribes as medical devices?
No. The MHRA guidance on ambient voice technology decides whether a product is a regulated medical device in Great Britain, which is a product classification question with direct consequences for a manufacturer. The FDA notice decides which internal FDA unit appears on an org chart. One changes a product's regulatory status, the other changes an address.
Last verified: July 29, 2026